Greg Divis, Avadel CEO
Little biotech makes deep cuts as it struggles to get narcolepsy drug approved amid months of regulatory limbo
Beleaguered by multiple delays, Avadel Pharmaceuticals is pulling out all the stops to try and clinch an FDA approval for its narcolepsy drug faster. But …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
